Addison’s disease associated with advanced HIV may explain the high mortality

Dr Joseph B Sempa

2024-09-19

Table of Contents

# Baseline table

\*\*Baseline table\*\*

| Variable | **N** | **N = 549**1 |
| --- | --- | --- |
| **Age at enrolment, median (IQR) (years)** | 547 | 36.0 (31.5, 43.0) |
| **Gender, n(%)** | 548 |  |
| Female |  | 280 (51.1%) |
| Male |  | 268 (48.9%) |
| **Ethnicity, n(%)** | 549 |  |
| Black African |  | 430 (78.3%) |
| Other |  | 119 (21.7%) |
| **Duration of current illness, median (IQR) (days)** | 514 | 14.0 (12.0, 21.0) |
| **Weight loss** | 525 | 452 (86.1%) |
| **Viral load, log10 copies/ml** | 121 | 10.8 (7.3, 12.3) |
| **Tuberculosis** | 549 | 461 (84.0%) |
| **PTB** | 549 | 348 (63.4%) |
| **EPTB** | 549 | 109 (19.9%) |
| **Cryptococcus neoformans** | 549 | 30 (5.5%) |
| **Pneumonia** | 549 | 62 (11.3%) |
| **Staph aureus** | 549 | 1 (0.2%) |
| **Kaposis sarcoma** | 549 | 6 (1.1%) |
| **Cytomegalovirus** | 549 | 1 (0.2%) |
| **HSV** | 549 | 8 (1.5%) |
| **HepB** | 549 | 18 (3.3%) |
| **Candida** | 549 | 34 (6.2%) |
| **GE/c diff** | 549 | 23 (4.2%) |
| **Parvo B19** | 549 | 1 (0.2%) |
| **Syphilis** | 549 | 17 (3.1%) |
| **B menigitis** | 549 | 6 (1.1%) |
| **UTI / Leptospirosis** | 549 | 7 (1.3%) |
| **PCP** | 549 | 5 (0.9%) |
| **COVID-19** | 549 | 2 (0.4%) |
| **Neurocysticercosis** | 549 | 2 (0.4%) |
| **Total CD4 count** | 542 | 33.5 (15.0, 62.0) |
| **White cell count X109** | 538 | 5.5 (3.7, 8.2) |
| **Lymphocyte count X109** | 124 | 0.8 (0.4, 1.9) |
| **Neutrophils** | 127 | 3.6 (1.5, 8.3) |
| **ART exposure** | 549 | 207 (37.7%) |
| **Kidney medication** | 549 | 52 (9.5%) |
| **Rifampicin** | 549 | 45 (8.2%) |
| **Fluconazole** | 549 | 74 (13.5%) |
| **Opiates** | 549 | 126 (23.0%) |
| 1Median (IQR); n (%) | | |

# Table 1

Table 2: ARV status

| Variable | **No**, N = 3411 | **Yes**, N = 2071 | **p-value**2 |
| --- | --- | --- | --- |
| **Age at enrolment** | 36.0 (31.0, 43.0) | 36.0 (32.0, 43.0) | 0.7 |
| **Gender, n(%)** |  |  | 0.4 |
| Female | 169 (49.6%) | 111 (53.6%) |  |
| Male | 172 (50.4%) | 96 (46.4%) |  |
| **Ethnicity, n(%)** |  |  | 0.2 |
| Asian | 1 (0.3%) | 0 (0.0%) |  |
| Black African | 258 (75.7%) | 172 (83.1%) |  |
| Coloured | 78 (22.9%) | 34 (16.4%) |  |
| White | 4 (1.2%) | 1 (0.5%) |  |
| **Duration of current illness, median (IQR) (days)** | 14.0 (12.0, 21.0) | 14.0 (10.0, 21.0) | 0.6 |
| **Weight loss** | 279 (86.6%) | 172 (85.1%) | 0.6 |
| **log10 viral load** | 10.6 (6.2, 12.3) | 10.8 (7.8, 12.3) | 0.5 |
| **Tuberculosis** | 282 (82.7%) | 179 (86.5%) | 0.2 |
| **PTB** | 218 (63.9%) | 130 (62.8%) | 0.8 |
| **EPTB** | 67 (19.6%) | 42 (20.3%) | 0.9 |
| **Cryptococcus neoformans** | 24 (7.0%) | 6 (2.9%) | 0.039 |
| **Pneumonia** | 38 (11.1%) | 24 (11.6%) | 0.9 |
| **Staph aureus** | 1 (0.3%) | 0 (0.0%) | >0.9 |
| **Kaposis sarcoma** | 3 (0.9%) | 3 (1.4%) | 0.7 |
| **Cytomegalovirus** | 1 (0.3%) | 0 (0.0%) | >0.9 |
| **HSV** | 3 (0.9%) | 5 (2.4%) | 0.2 |
| **HepB** | 10 (2.9%) | 8 (3.9%) | 0.6 |
| **Candida** | 23 (6.7%) | 11 (5.3%) | 0.5 |
| **GE/c diff** | 11 (3.2%) | 12 (5.8%) | 0.15 |
| **Parvo B19** | 0 (0.0%) | 1 (0.5%) | 0.4 |
| **Syphilis** | 14 (4.1%) | 3 (1.4%) | 0.082 |
| **B menigitis** | 4 (1.2%) | 2 (1.0%) | >0.9 |
| **UTI / Leptospirosis** | 4 (1.2%) | 3 (1.4%) | >0.9 |
| **PCP** | 5 (1.5%) | 0 (0.0%) | 0.2 |
| **COVID-19** | 2 (0.6%) | 0 (0.0%) | 0.5 |
| **Neurocysticercosis** | 0 (0.0%) | 2 (1.0%) | 0.14 |
| **Total CD4 count** | 32.5 (13.3, 61.8) | 34.0 (16.0, 61.5) | 0.8 |
| **White cell count X109** | 5.2 (3.4, 7.6) | 5.8 (4.0, 8.9) | 0.076 |
| **Lymphocyte count X109** | 0.9 (0.4, 3.9) | 0.7 (0.4, 1.3) | 0.2 |
| **Neutrophils** | 3.7 (1.5, 8.3) | 3.3 (1.7, 7.4) | 0.8 |
| **Kidney medication** | 30 (8.8%) | 22 (10.6%) | 0.5 |
| **Rifampicin** | 22 (6.5%) | 23 (11.1%) | 0.054 |
| **Fluconazole** | 45 (13.2%) | 29 (14.0%) | 0.8 |
| **Opiates** | 97 (28.4%) | 29 (14.0%) | <0.001 |
| 1Median (IQR); n (%) | | | |
| 2Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test | | | |

# Table 1.2

Table 3: Patient presentation by CD4 count category


| Variable | **Overall**, N = 5421 | **0 - 33**, N = 2711 | **34 - 66**, N = 1521 | **67 - 100**, N = 1191 | **p-value**2 |
| --- | --- | --- | --- | --- | --- |
| **Age at enrolment, median (IQR) (years)** | 36.0 (31.3, 43.0) | 35.0 (30.5, 42.0) | 37.0 (32.0, 43.3) | 37.0 (33.0, 46.0) | 0.016 |
| **Gender, n(%)** |  |  |  |  | 0.3 |
| Female | 277 (51.2%) | 137 (50.6%) | 85 (55.9%) | 55 (46.6%) |  |
| Male | 264 (48.8%) | 134 (49.4%) | 67 (44.1%) | 63 (53.4%) |  |
| **Ethnicity, n(%)** |  |  |  |  | 0.3 |
| Black African | 426 (78.6%) | 220 (81.2%) | 117 (77.0%) | 89 (74.8%) |  |
| Other | 116 (21.4%) | 51 (18.8%) | 35 (23.0%) | 30 (25.2%) |  |
| **Duration of current illness, median (IQR) (days)** | 14.0 (12.0, 21.0) | 14.0 (14.0, 21.0) | 14.0 (12.5, 22.5) | 14.0 (7.0, 21.0) | 0.036 |
| **Weight loss** | 452 (86.4%) | 231 (87.5%) | 129 (87.2%) | 92 (82.9%) | 0.5 |
| **log10 viral load** | 10.8 (7.3, 12.3) | 11.6 (9.3, 12.8) | 8.9 (6.5, 12.2) | 7.3 (3.9, 10.6) | <0.001 |
| **Tuberculosis** | 459 (84.7%) | 230 (84.9%) | 131 (86.2%) | 98 (82.4%) | 0.7 |
| **PTB** | 346 (63.8%) | 178 (65.7%) | 90 (59.2%) | 78 (65.5%) | 0.4 |
| **EPTB** | 109 (20.1%) | 53 (19.6%) | 40 (26.3%) | 16 (13.4%) | 0.030 |
| **Cryptococcus neoformans** | 30 (5.5%) | 16 (5.9%) | 5 (3.3%) | 9 (7.6%) | 0.3 |
| **Pneumonia** | 62 (11.4%) | 30 (11.1%) | 19 (12.5%) | 13 (10.9%) | 0.9 |
| **Staph aureus** | 1 (0.2%) | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) | >0.9 |
| **Kaposis sarcoma** | 6 (1.1%) | 6 (2.2%) | 0 (0.0%) | 0 (0.0%) | 0.055 |
| **Cytomegalovirus** | 1 (0.2%) | 0 (0.0%) | 1 (0.7%) | 0 (0.0%) | 0.5 |
| **HSV** | 8 (1.5%) | 3 (1.1%) | 4 (2.6%) | 1 (0.8%) | 0.4 |
| **HepB** | 18 (3.3%) | 9 (3.3%) | 8 (5.3%) | 1 (0.8%) | 0.13 |
| **Candida** | 34 (6.3%) | 21 (7.7%) | 11 (7.2%) | 2 (1.7%) | 0.064 |
| **GE/c diff** | 23 (4.2%) | 12 (4.4%) | 7 (4.6%) | 4 (3.4%) | 0.9 |
| **Parvo B19** | 1 (0.2%) | 0 (0.0%) | 1 (0.7%) | 0 (0.0%) | 0.5 |
| **Syphilis** | 16 (3.0%) | 8 (3.0%) | 7 (4.6%) | 1 (0.8%) | 0.2 |
| **B menigitis** | 6 (1.1%) | 3 (1.1%) | 1 (0.7%) | 2 (1.7%) | 0.8 |
| **UTI / Leptospirosis** | 7 (1.3%) | 4 (1.5%) | 0 (0.0%) | 3 (2.5%) | 0.13 |
| **PCP** | 5 (0.9%) | 4 (1.5%) | 1 (0.7%) | 0 (0.0%) | 0.5 |
| **COVID-19** | 2 (0.4%) | 1 (0.4%) | 1 (0.7%) | 0 (0.0%) | >0.9 |
| **Neurocysticercosis** | 2 (0.4%) | 1 (0.4%) | 1 (0.7%) | 0 (0.0%) | >0.9 |
| **White cell count X109** | 5.4 (3.7, 8.1) | 5.0 (2.9, 7.4) | 5.8 (4.2, 8.4) | 6.8 (4.5, 9.7) | <0.001 |
| **Lymphocyte count X109** | 0.8 (0.4, 1.9) | 0.6 (0.3, 1.3) | 0.9 (0.5, 5.8) | 1.3 (0.8, 3.0) | 0.011 |
| **Neutrophils** | 3.6 (1.5, 8.3) | 2.4 (1.0, 5.9) | 6.6 (2.8, 15.7) | 5.1 (2.9, 11.5) | 0.002 |
| **ART exposure** | 207 (38.2%) | 101 (37.3%) | 62 (40.8%) | 44 (37.0%) | 0.7 |
| **Kidney medication** | 52 (9.6%) | 27 (10.0%) | 16 (10.5%) | 9 (7.6%) | 0.7 |
| **TB medication** | 14 (2.6%) | 5 (1.8%) | 3 (2.0%) | 6 (5.0%) | 0.2 |
| **Fungal medication** | 6 (1.1%) | 2 (0.7%) | 1 (0.7%) | 3 (2.5%) | 0.3 |
| **Rifampicin** | 45 (8.3%) | 22 (8.1%) | 11 (7.2%) | 12 (10.1%) | 0.7 |
| **Fluconazole** | 74 (13.7%) | 47 (17.3%) | 17 (11.2%) | 10 (8.4%) | 0.035 |
| **Opiates** | 125 (23.1%) | 63 (23.2%) | 31 (20.4%) | 31 (26.1%) | 0.5 |
| 1Median (IQR); n (%) | | | | | |
| 2Kruskal-Wallis rank sum test; Pearson's Chi-squared test; Fisher's exact test | | | | | |

# A tibble: 4 × 17

Group .y. group1 group2 n1 n2 statistic df p p.adj 1 Random cort… resu… Adren… No Ad… 27 407 -8.91 38.2 7.17e-11 2.87e-10 2 Basal corti… resu… Adren… No Ad… 27 124 -6.51 58.6 1.88e- 8 7.52e- 8 3 Stimulated … resu… Adren… No Ad… 27 121 -14.5 61.7 1.36e-21 5.44e-21 4 ACTH resu… Adren… No Ad… 27 407 1.34 26.9 1.92e- 1 7.68e- 1 # ℹ 7 more variables: p.adj.signif , y.position , # groups , x , xmin , xmax , p.adj\_1 png 2 # A tibble: 2 × 16 Group .y. group1 group2 n1 n2 statistic df p p.adj p.adj.signif   
1 ART … CD4 … No Yes 335 207 -0.107 448. 0.915 1 ns  
2 Kidn… CD4 … No Yes 490 52 0.287 61.6 0.775 1 ns  
# ℹ 5 more variables: y.position , groups , x , # xmin , xmax png 2

Table 3.1: addisons disease and medication

| Variable | **Overall**, N = 5491 | **No AI**, N = 5221 | **SAI**, N = 201 | **PAI**, N = 71 | **p-value**2 |
| --- | --- | --- | --- | --- | --- |
| **ART exposure** | 207 (37.7%) | 201 (38.5%) | 4 (20.0%) | 2 (28.6%) | 0.2 |
| **Kidney medication** | 52 (9.5%) | 47 (9.0%) | 3 (15.0%) | 2 (28.6%) | 0.10 |
| **TB medication** | 14 (2.6%) | 14 (2.7%) | 0 (0.0%) | 0 (0.0%) | >0.9 |
| **Fungal medication** | 6 (1.1%) | 6 (1.1%) | 0 (0.0%) | 0 (0.0%) | >0.9 |
| 1n (%) | | | | | |
| 2Fisher's exact test | | | | | |






# Table 2: comparing Addisons status with other variables

Table 2: Should compare Total AI with Non-AI patients

|  | **Non-AI vs AI** | | | **PAI vs SAI patients** | | |
| --- | --- | --- | --- | --- | --- | --- |
| Variable | **No Adrenal insufficiency**, N = 5221 | **Adrenal insufficiency**, N = 271 | **p-value**2 | **SAI**, N = 201 | **PAI**, N = 71 | **p-value**3 |
| **Age at enrolment, median (IQR) (years)** | 36.0 (31.8, 43.0) | 36.0 (32.0, 47.5) | 0.4 | 36.0 (32.0, 48.5) | 40.0 (35.0, 45.0) | 0.6 |
| **Gender, n(%)** |  |  | >0.9 |  |  | 0.7 |
| Female | 266 (51.1%) | 14 (51.9%) |  | 11 (55.0%) | 3 (42.9%) |  |
| Male | 255 (48.9%) | 13 (48.1%) |  | 9 (45.0%) | 4 (57.1%) |  |
| **Ethnicity, n(%)** |  |  | 0.4 |  |  | >0.9 |
| Black African | 407 (78.0%) | 23 (85.2%) |  | 17 (85.0%) | 6 (85.7%) |  |
| Other | 115 (22.0%) | 4 (14.8%) |  | 3 (15.0%) | 1 (14.3%) |  |
| **Duration of current illness, median (IQR) (days)** | 14.0 (11.8, 21.0) | 14.0 (14.0, 27.8) | 0.4 | 21.0 (14.0, 30.0) | 10.0 (7.0, 12.5) | 0.019 |
| **Weight loss** | 430 (86.3%) | 22 (81.5%) | 0.4 | 15 (75.0%) | 7 (100.0%) | 0.3 |
| **Viral load (log10 Copies/mL)** | 10.8 (7.1, 12.3) | 11.0 (10.7, 11.3) | 0.9 | 10.5 (10.5, 10.5) | 11.6 (11.6, 11.6) | >0.9 |
| **Tuberculosis** | 440 (84.3%) | 21 (77.8%) | 0.4 | 16 (80.0%) | 5 (71.4%) | 0.6 |
| **PTB** | 337 (64.6%) | 11 (40.7%) | 0.012 | 8 (40.0%) | 3 (42.9%) | >0.9 |
| **EPTB** | 99 (19.0%) | 10 (37.0%) | 0.022 | 8 (40.0%) | 2 (28.6%) | 0.7 |
| **Cryptococcus neoformans** | 20 (3.8%) | 10 (37.0%) | <0.001 | 7 (35.0%) | 3 (42.9%) | >0.9 |
| **Pneumonia** | 59 (11.3%) | 3 (11.1%) | >0.9 | 3 (15.0%) | 0 (0.0%) | 0.5 |
| **Staph aureus** | 0 (0.0%) | 1 (3.7%) | 0.049 | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **Kaposis sarcoma** | 5 (1.0%) | 1 (3.7%) | 0.3 | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **Cytomegalovirus** | 0 (0.0%) | 1 (3.7%) | 0.049 | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **HSV** | 7 (1.3%) | 1 (3.7%) | 0.3 | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **HepB** | 16 (3.1%) | 2 (7.4%) | 0.2 | 2 (10.0%) | 0 (0.0%) | >0.9 |
| **Candida** | 33 (6.3%) | 1 (3.7%) | >0.9 | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **GE/c diff** | 23 (4.4%) | 0 (0.0%) | 0.6 | 0 (0.0%) | 0 (0.0%) |  |
| **Parvo B19** | 0 (0.0%) | 1 (3.7%) | 0.049 | 0 (0.0%) | 1 (14.3%) | 0.3 |
| **Syphilis** | 17 (3.3%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **B menigitis** | 6 (1.1%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **UTI / Leptospirosis** | 7 (1.3%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **PCP** | 5 (1.0%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **COVID-19** | 2 (0.4%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Neurocysticercosis** | 2 (0.4%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Total CD4 count** | 34.0 (15.0, 63.0) | 28.0 (13.5, 49.5) | 0.4 | 19.0 (10.0, 48.8) | 46.0 (25.5, 61.0) | 0.2 |
| **White cell count X109** | 5.6 (3.8, 8.1) | 5.2 (2.8, 8.9) | 0.5 | 5.3 (2.8, 11.9) | 3.5 (3.0, 5.5) | 0.4 |
| **Lymphocyte count X109** | 0.8 (0.4, 2.0) | 0.9 (0.5, 1.2) | 0.7 | 0.7 (0.5, 1.0) | 1.3 (1.3, 1.3) | 0.6 |
| **Neutrophils** | 3.8 (1.6, 8.9) | 1.3 (0.9, 1.6) | 0.037 | 1.5 (1.0, 1.7) | 0.9 (0.9, 0.9) | 0.7 |
| **Sodium mmol/L** | 133.0 (130.0, 137.0) | 135.0 (133.0, 137.5) | 0.033 | 135.5 (134.0, 137.3) | 133.0 (131.5, 136.5) | 0.2 |
| **Potassium mmol/L** | 4.1 (3.6, 4.6) | 3.9 (3.3, 4.3) | 0.069 | 4.0 (3.3, 4.5) | 3.6 (3.3, 3.9) | 0.4 |
| **Haemoglobin g/dL** | 8.7 (7.4, 10.3) | 8.7 (7.6, 10.4) | 0.6 | 8.7 (7.6, 10.7) | 10.2 (7.9, 10.3) | 0.7 |
| **BP (systolic)** | 111.0 (102.0, 125.0) | 120.0 (102.5, 128.5) | 0.4 | 118.0 (99.5, 129.3) | 120.0 (120.0, 123.5) | 0.7 |
| **BP (diastolic)** | 70.0 (60.0, 79.0) | 71.0 (66.5, 80.0) | 0.080 | 72.0 (60.0, 80.0) | 70.0 (70.0, 82.0) | 0.8 |
| **Heart rate** | 91.0 (79.0, 108.8) | 87.0 (78.5, 107.0) | 0.7 | 85.0 (76.8, 102.3) | 97.0 (88.0, 111.0) | 0.10 |
| **Hypotension** | 46 (9.3%) | 1 (3.7%) | 0.5 | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **Weakness** | 422 (85.1%) | 21 (77.8%) | 0.3 | 17 (85.0%) | 4 (57.1%) | 0.3 |
| **Tiredness** | 423 (85.1%) | 23 (85.2%) | >0.9 | 18 (90.0%) | 5 (71.4%) | 0.3 |
| **Poor appetite** | 374 (75.9%) | 22 (81.5%) | 0.5 | 16 (80.0%) | 6 (85.7%) | >0.9 |
| **Increased pigmentation of the skin** | 247 (50.8%) | 9 (37.5%) | 0.2 | 6 (31.6%) | 3 (60.0%) | 0.3 |
| **Nausea** | 263 (53.0%) | 16 (59.3%) | 0.5 | 11 (55.0%) | 5 (71.4%) | 0.7 |
| **Vomiting** | 137 (27.7%) | 8 (29.6%) | 0.8 | 4 (20.0%) | 4 (57.1%) | 0.14 |
| **Liking for salt** | 262 (53.0%) | 19 (70.4%) | 0.078 | 14 (70.0%) | 5 (71.4%) | >0.9 |
| **Hypoglycaemia** | 11 (2.2%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Loss of consciousness** | 7 (1.4%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Diarrhoea** | 219 (44.5%) | 8 (29.6%) | 0.13 | 7 (35.0%) | 1 (14.3%) | 0.6 |
| **Dizziness** | 236 (47.8%) | 13 (50.0%) | 0.8 | 9 (45.0%) | 4 (66.7%) | 0.6 |
| **Shock** | 5 (1.0%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Anorexia** | 234 (47.3%) | 8 (29.6%) | 0.073 | 4 (20.0%) | 4 (57.1%) | 0.14 |
| **Loss of axillary and pubic hair, if female** |  |  | 0.5 |  |  | 0.8 |
| No | 159 (31.7%) | 11 (40.7%) |  | 9 (45.0%) | 2 (28.6%) |  |
| Not applicable | 248 (49.4%) | 13 (48.1%) |  | 9 (45.0%) | 4 (57.1%) |  |
| Yes | 95 (18.9%) | 3 (11.1%) |  | 2 (10.0%) | 1 (14.3%) |  |
| **Any postural drop in blood pressure** | 21 (4.3%) | 2 (7.4%) | 0.3 | 2 (10.0%) | 0 (0.0%) | >0.9 |
| **Presence of anaemia** | 290 (58.8%) | 13 (50.0%) | 0.4 | 9 (47.4%) | 4 (57.1%) | >0.9 |
| **mortality** | 60 (43.5%) | 6 (50.0%) | 0.7 | 4 (44.4%) | 2 (66.7%) | >0.9 |
| **ART exposure** | 201 (38.5%) | 6 (22.2%) | 0.089 | 4 (20.0%) | 2 (28.6%) | 0.6 |
| **Kidney medication** | 47 (9.0%) | 5 (18.5%) | 0.2 | 3 (15.0%) | 2 (28.6%) | 0.6 |
| **Rifampicin** |  |  |  | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **Fluconazole** |  |  |  | 8 (40.0%) | 3 (42.9%) | >0.9 |
| **Opiates** |  |  |  | 10 (50.0%) | 2 (28.6%) | 0.4 |
| 1Median (IQR); n (%) | | | | | | |
| 2Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test | | | | | | |
| 3Wilcoxon rank sum test; Fisher's Exact Test for Count Data; Wilcoxon rank sum exact test; Fisher's Exact Test for Count Data with simulated p-value  (based on 2000 replicates) | | | | | | |

# Table 2.2: Cause of moratlity

# Dotplot

png 2 png 2 png 2

# Table 3: Bivariate table

# Table 3a: Deep dive on Addison’s disease patients

Mortality: Non-AI vs AI

| Variable | **AI deaths**, N = 81 | **Alive without AI**, N = 2461 | **p-value**2 |
| --- | --- | --- | --- |
| **Age at enrolment, median (IQR) (years)** | 41 (37, 44) | 35 (31, 41) | 0.2 |
| **Gender, n(%)** |  |  | >0.9 |
| Female | 4 (50.0%) | 115 (46.7%) |  |
| Male | 4 (50.0%) | 131 (53.3%) |  |
| **Ethnicity, n(%)** |  |  | 0.6 |
| Black African | 6 (75.0%) | 203 (82.5%) |  |
| Other | 2 (25.0%) | 43 (17.5%) |  |
| **Duration of current illness, median (IQR) (days)** | 14 (11, 14) | 14 (14, 21) | 0.3 |
| **Weight loss** | 6 (75.0%) | 223 (93.7%) | 0.10 |
| **Viral load (log10 Copies/mL)** | NA (NA, NA) | 10.14 (7.00, 12.29) |  |
| **Tuberculosis** | 7 (87.5%) | 220 (89.4%) | 0.6 |
| **Cryptococcus neoformans** | 4 (50.0%) | 8 (3.3%) | <0.001 |
| **Pneumonia** | 0 (0.0%) | 38 (15.4%) | 0.6 |
| **Staph aureus** | 0 (0.0%) | 0 (0.0%) |  |
| **Kaposis sarcoma** | 0 (0.0%) | 2 (0.8%) | >0.9 |
| **Cytomegalovirus** | 0 (0.0%) | 0 (0.0%) |  |
| **HSV** | 0 (0.0%) | 3 (1.2%) | >0.9 |
| **HepB** | 1 (12.5%) | 7 (2.8%) | 0.2 |
| **Candida** | 0 (0.0%) | 11 (4.5%) | >0.9 |
| **GE/c diff** | 0 (0.0%) | 11 (4.5%) | >0.9 |
| **Parvo B19** | 0 (0.0%) | 0 (0.0%) |  |
| **Syphilis** | 0 (0.0%) | 4 (1.6%) | >0.9 |
| **B menigitis** | 0 (0.0%) | 1 (0.4%) | >0.9 |
| **UTI / Leptospirosis** | 0 (0.0%) | 3 (1.2%) | >0.9 |
| **PCP** | 0 (0.0%) | 1 (0.4%) | >0.9 |
| **COVID-19** | 0 (0.0%) | 0 (0.0%) |  |
| **Neurocysticercosis** | 0 (0.0%) | 0 (0.0%) |  |
| **Total CD4 count** | 20 (17, 44) | 34 (15, 65) | 0.6 |
| **White cell count X109** | 8.3 (4.9, 34.5) | 5.7 (3.9, 8.9) | 0.2 |
| **Lymphocyte count X109** | NA (NA, NA) | 0.5 (0.3, 1.7) |  |
| **Neutrophils** | NA (NA, NA) | 4 (1, 10) |  |
| **Sodium mmol/L** | 133.5 (132.5, 139.0) | 134.0 (130.0, 137.0) | 0.4 |
| **Potassium mmol/L** | 3.85 (3.52, 4.00) | 4.10 (3.70, 4.60) | 0.13 |
| **Haemoglobin g/dL** | 9.55 (7.60, 10.65) | 8.90 (7.60, 10.45) | 0.8 |
| **BP (systolic)** | 128 (115, 131) | 110 (100, 126) | 0.2 |
| **BP (diastolic)** | 74 (62, 79) | 68 (60, 76) | 0.3 |
| **Heart rate** | 87 (67, 101) | 94 (81, 111) | 0.3 |
| **Hypotension** | 0 (0.0%) | 15 (6.4%) | >0.9 |
| **Weakness** | 6 (75.0%) | 205 (86.9%) | 0.3 |
| **Tiredness** | 8 (100.0%) | 213 (89.5%) | >0.9 |
| **Poor appetite** | 8 (100.0%) | 176 (75.2%) | 0.2 |
| **Increased pigmentation of the skin** | 3 (42.9%) | 108 (47.2%) | >0.9 |
| **Nausea** | 6 (75.0%) | 120 (50.6%) | 0.3 |
| **Vomiting** | 2 (25.0%) | 69 (29.2%) | >0.9 |
| **Liking for salt** | 6 (75.0%) | 155 (65.7%) | 0.7 |
| **Hypoglycaemia** | 0 (0.0%) | 6 (2.5%) | >0.9 |
| **Loss of consciousness** | 0 (0.0%) | 1 (0.4%) | >0.9 |
| **Diarrhoea** | 2 (25.0%) | 97 (41.5%) | 0.5 |
| **Dizziness** | 4 (50.0%) | 107 (45.1%) | >0.9 |
| **Shock** | 0 (0.0%) | 2 (0.8%) | >0.9 |
| **Anorexia** | 3 (37.5%) | 106 (44.9%) | 0.7 |
| **Loss of axillary and pubic hair, if female** |  |  | 0.9 |
| No | 3 (37.5%) | 75 (31.0%) |  |
| Not applicable | 4 (50.0%) | 129 (53.3%) |  |
| Yes | 1 (12.5%) | 38 (15.7%) |  |
| **Any postural drop in blood pressure** | 0 (0.0%) | 7 (3.0%) | >0.9 |
| **Presence of anaemia** | 5 (62.5%) | 123 (52.3%) | 0.7 |
| **ART exposure** | 1 (12.5%) | 99 (40.2%) | 0.2 |
| **Kidney medication** | 2 (25.0%) | 21 (8.5%) | 0.2 |
| **Rifampicin** | 0 (0.0%) | 24 (9.8%) | >0.9 |
| **Fluconazole** | 5 (62.5%) | 31 (12.6%) | 0.002 |
| **Opiates** | 3 (37.5%) | 71 (28.9%) | 0.7 |
| **incremental\_cortisol** | 41 (26, 142) | 283 (196, 386) | <0.001 |
| 1Median (IQR); n (%) | | | |
| 2Wilcoxon rank sum test; Fisher's exact test | | | |

Table 2.2.1: Mortality; PAI SAI

| Variable | **PAI**, N = 31 | **SAI**, N = 51 | **p-value**2 |
| --- | --- | --- | --- |
| **mortality with Addisons disease** |  |  |  |
| Die | 3 (100.0%) | 5 (100.0%) |  |
| **Age at enrolment median (IQR) (years)** |  |  | >0.9 |
| 29 | 0 (0.0%) | 1 (20.0%) |  |
| 31 | 1 (33.3%) | 0 (0.0%) |  |
| 39 | 1 (33.3%) | 0 (0.0%) |  |
| 40 | 1 (33.3%) | 0 (0.0%) |  |
| 41 | 0 (0.0%) | 1 (20.0%) |  |
| 42 | 0 (0.0%) | 1 (20.0%) |  |
| 48 | 0 (0.0%) | 1 (20.0%) |  |
| 50 | 0 (0.0%) | 1 (20.0%) |  |
| **Gender, n(%)** |  |  | >0.9 |
| Female | 1 (33.3%) | 3 (60.0%) |  |
| Male | 2 (66.7%) | 2 (40.0%) |  |
| **Ethnicity, n(%)** |  |  | 0.5 |
| Black African | 3 (100.0%) | 3 (60.0%) |  |
| Other | 0 (0.0%) | 2 (40.0%) |  |
| **Duration of current illness, median (IQR) (days)** |  |  | >0.9 |
| 4 | 1 (33.3%) | 0 (0.0%) |  |
| 7 | 0 (0.0%) | 1 (20.0%) |  |
| 9 | 0 (0.0%) | 1 (20.0%) |  |
| 23 | 1 (33.3%) | 0 (0.0%) |  |
| 236 | 1 (33.3%) | 0 (0.0%) |  |
| 3630 | 0 (0.0%) | 1 (20.0%) |  |
| 5528 | 0 (0.0%) | 1 (20.0%) |  |
| 7754 | 0 (0.0%) | 1 (20.0%) |  |
| **Random cortisol** |  |  | >0.9 |
| 237 | 0 (0.0%) | 1 (20.0%) |  |
| 251 | 0 (0.0%) | 1 (20.0%) |  |
| 255 | 0 (0.0%) | 1 (20.0%) |  |
| 281 | 1 (33.3%) | 0 (0.0%) |  |
| 332 | 0 (0.0%) | 1 (20.0%) |  |
| 337 | 0 (0.0%) | 1 (20.0%) |  |
| 344 | 1 (33.3%) | 0 (0.0%) |  |
| 404 | 1 (33.3%) | 0 (0.0%) |  |
| **Basal cortisol** |  |  | >0.9 |
| 128 | 1 (33.3%) | 0 (0.0%) |  |
| 192 | 0 (0.0%) | 1 (20.0%) |  |
| 228 | 0 (0.0%) | 1 (20.0%) |  |
| 266 | 0 (0.0%) | 1 (20.0%) |  |
| 301 | 0 (0.0%) | 1 (20.0%) |  |
| 315 | 1 (33.3%) | 0 (0.0%) |  |
| 381 | 0 (0.0%) | 1 (20.0%) |  |
| 400 | 1 (33.3%) | 0 (0.0%) |  |
| **Stimulated cortisol** |  |  | >0.9 |
| 296 | 0 (0.0%) | 1 (20.0%) |  |
| 316 | 0 (0.0%) | 1 (20.0%) |  |
| 335 | 0 (0.0%) | 1 (20.0%) |  |
| 347 | 1 (33.3%) | 0 (0.0%) |  |
| 403 | 1 (33.3%) | 0 (0.0%) |  |
| 428 | 1 (33.3%) | 0 (0.0%) |  |
| 431 | 0 (0.0%) | 1 (20.0%) |  |
| 438 | 0 (0.0%) | 1 (20.0%) |  |
| **ACTH** |  |  | >0.9 |
| 7.40000009536743 | 0 (0.0%) | 1 (20.0%) |  |
| 22 | 0 (0.0%) | 1 (20.0%) |  |
| 24.8999996185303 | 0 (0.0%) | 1 (20.0%) |  |
| 36.9000015258789 | 0 (0.0%) | 1 (20.0%) |  |
| 47.9000015258789 | 0 (0.0%) | 1 (20.0%) |  |
| 72.0999984741211 | 1 (33.3%) | 0 (0.0%) |  |
| 87.6999969482422 | 1 (33.3%) | 0 (0.0%) |  |
| 312.600006103516 | 1 (33.3%) | 0 (0.0%) |  |
| **incremental\_cortisol** |  |  | >0.9 |
| 3 | 1 (33.3%) | 0 (0.0%) |  |
| 15 | 0 (0.0%) | 1 (20.0%) |  |
| 30 | 0 (0.0%) | 1 (20.0%) |  |
| 32 | 1 (33.3%) | 0 (0.0%) |  |
| 50 | 0 (0.0%) | 1 (20.0%) |  |
| 107 | 0 (0.0%) | 1 (20.0%) |  |
| 246 | 0 (0.0%) | 1 (20.0%) |  |
| 300 | 1 (33.3%) | 0 (0.0%) |  |
| **BP (systolic)** |  |  | >0.9 |
| 95 | 0 (0.0%) | 1 (20.0%) |  |
| 100 | 0 (0.0%) | 1 (20.0%) |  |
| 120 | 1 (33.3%) | 0 (0.0%) |  |
| 127 | 1 (33.3%) | 0 (0.0%) |  |
| 128 | 0 (0.0%) | 1 (20.0%) |  |
| 130 | 0 (0.0%) | 1 (20.0%) |  |
| 134 | 1 (33.3%) | 0 (0.0%) |  |
| 140 | 0 (0.0%) | 1 (20.0%) |  |
| **BP (diastolic)** |  |  | >0.9 |
| 55 | 0 (0.0%) | 1 (20.0%) |  |
| 60 | 0 (0.0%) | 1 (20.0%) |  |
| 63 | 1 (33.3%) | 0 (0.0%) |  |
| 71 | 0 (0.0%) | 1 (20.0%) |  |
| 76 | 0 (0.0%) | 1 (20.0%) |  |
| 79 | 1 (33.3%) | 0 (0.0%) |  |
| 80 | 0 (0.0%) | 1 (20.0%) |  |
| 86 | 1 (33.3%) | 0 (0.0%) |  |
| **Heart rate** |  |  | >0.9 |
| 49 | 0 (0.0%) | 1 (20.0%) |  |
| 65 | 0 (0.0%) | 1 (20.0%) |  |
| 68 | 0 (0.0%) | 1 (20.0%) |  |
| 82 | 0 (0.0%) | 1 (20.0%) |  |
| 92 | 1 (33.3%) | 0 (0.0%) |  |
| 100 | 0 (0.0%) | 1 (20.0%) |  |
| 105 | 1 (33.3%) | 0 (0.0%) |  |
| 139 | 1 (33.3%) | 0 (0.0%) |  |
| **Hypotension** | 0 (0.0%) | 0 (0.0%) |  |
| **Weakness** | 2 (66.7%) | 4 (80.0%) | >0.9 |
| **Tiredness** | 3 (100.0%) | 5 (100.0%) |  |
| **Poor appetite** | 3 (100.0%) | 5 (100.0%) |  |
| **Weight loss** | 3 (100.0%) | 3 (60.0%) | 0.5 |
| **Increased pigmentation of the skin** | 3 (100.0%) | 0 (0.0%) | 0.029 |
| **Nausea** | 3 (100.0%) | 3 (60.0%) | 0.5 |
| **Vomiting** | 2 (66.7%) | 0 (0.0%) | 0.11 |
| **Liking for salt** | 2 (66.7%) | 4 (80.0%) | >0.9 |
| **Hypoglycaemia** | 0 (0.0%) | 0 (0.0%) |  |
| **Loss of consciousness** | 0 (0.0%) | 0 (0.0%) |  |
| **Diarrhoea** | 1 (33.3%) | 1 (20.0%) | >0.9 |
| **Dizziness** | 3 (100.0%) | 1 (20.0%) | 0.14 |
| **Shock** | 0 (0.0%) | 0 (0.0%) |  |
| **Anorexia** | 3 (100.0%) | 0 (0.0%) | 0.018 |
| **Loss of axillary and pubic hair, if female** |  |  | 0.3 |
| No | 0 (0.0%) | 3 (60.0%) |  |
| Not applicable | 2 (66.7%) | 2 (40.0%) |  |
| Yes | 1 (33.3%) | 0 (0.0%) |  |
| **Any postural drop in blood pressure** | 0 (0.0%) | 0 (0.0%) |  |
| **Presence of anaemia** | 3 (100.0%) | 2 (40.0%) | 0.2 |
| **Tuberculosis** | 3 (100.0%) | 4 (80.0%) | >0.9 |
| **PTB** | 2 (66.7%) | 1 (20.0%) | 0.5 |
| **EPTB** | 1 (33.3%) | 3 (60.0%) | >0.9 |
| **Cryptococcus neoformans** | 1 (33.3%) | 3 (60.0%) | >0.9 |
| **Pneumonia** | 0 (0.0%) | 0 (0.0%) |  |
| **Staph aureus** | 0 (0.0%) | 0 (0.0%) |  |
| **Kaposis sarcoma** | 0 (0.0%) | 0 (0.0%) |  |
| **Cytomegalovirus** | 0 (0.0%) | 0 (0.0%) |  |
| **HSV** | 0 (0.0%) | 0 (0.0%) |  |
| **HepB** | 0 (0.0%) | 1 (20.0%) | >0.9 |
| **Candida** | 0 (0.0%) | 0 (0.0%) |  |
| **GE/c diff** | 0 (0.0%) | 0 (0.0%) |  |
| **Parvo B19** | 0 (0.0%) | 0 (0.0%) |  |
| **Syphilis** | 0 (0.0%) | 0 (0.0%) |  |
| **B menigitis** | 0 (0.0%) | 0 (0.0%) |  |
| **UTI / Leptospirosis** | 0 (0.0%) | 0 (0.0%) |  |
| **PCP** | 0 (0.0%) | 0 (0.0%) |  |
| **COVID-19** | 0 (0.0%) | 0 (0.0%) |  |
| **Neurocysticercosis** | 0 (0.0%) | 0 (0.0%) |  |
| **Viral load (log10 Copies/mL)** | NA (NA, NA) | NA (NA, NA) |  |
| **Total CD4 count** |  |  | 0.5 |
| 13 | 0 (0.0%) | 1 (20.0%) |  |
| 15 | 1 (33.3%) | 0 (0.0%) |  |
| 17 | 0 (0.0%) | 2 (40.0%) |  |
| 23 | 1 (33.3%) | 0 (0.0%) |  |
| 43 | 0 (0.0%) | 1 (20.0%) |  |
| 46 | 1 (33.3%) | 0 (0.0%) |  |
| 98 | 0 (0.0%) | 1 (20.0%) |  |
| **Sodium mmol/L** |  |  | 0.9 |
| 131 | 0 (0.0%) | 2 (40.0%) |  |
| 133 | 1 (33.3%) | 1 (20.0%) |  |
| 134 | 1 (33.3%) | 0 (0.0%) |  |
| 139 | 1 (33.3%) | 1 (20.0%) |  |
| 141 | 0 (0.0%) | 1 (20.0%) |  |
| **Potassium mmol/L** |  |  | 0.5 |
| 2.79999995231628 | 0 (0.0%) | 1 (20.0%) |  |
| 3.29999995231628 | 1 (33.3%) | 0 (0.0%) |  |
| 3.59999990463257 | 1 (33.3%) | 0 (0.0%) |  |
| 3.79999995231628 | 0 (0.0%) | 1 (20.0%) |  |
| 3.90000009536743 | 0 (0.0%) | 1 (20.0%) |  |
| 4 | 0 (0.0%) | 2 (40.0%) |  |
| 5.40000009536743 | 1 (33.3%) | 0 (0.0%) |  |
| **Haemoglobin g/dL** |  |  | >0.9 |
| 5.80000019073486 | 0 (0.0%) | 1 (20.0%) |  |
| 6.09999990463257 | 0 (0.0%) | 1 (20.0%) |  |
| 8.10000038146973 | 1 (33.3%) | 0 (0.0%) |  |
| 8.69999980926514 | 0 (0.0%) | 1 (20.0%) |  |
| 10.3999996185303 | 1 (33.3%) | 0 (0.0%) |  |
| 10.5 | 0 (0.0%) | 1 (20.0%) |  |
| 11.1000003814697 | 0 (0.0%) | 1 (20.0%) |  |
| 13.6999998092651 | 1 (33.3%) | 0 (0.0%) |  |
| **White cell count X109** |  |  | >0.9 |
| 2.67000007629395 | 1 (33.3%) | 0 (0.0%) |  |
| 3.86999988555908 | 0 (0.0%) | 1 (20.0%) |  |
| 5.19999980926514 | 1 (33.3%) | 0 (0.0%) |  |
| 5.75 | 1 (33.3%) | 0 (0.0%) |  |
| 10.8400001525879 | 0 (0.0%) | 1 (20.0%) |  |
| 33 | 0 (0.0%) | 1 (20.0%) |  |
| 39 | 0 (0.0%) | 1 (20.0%) |  |
| 411 | 0 (0.0%) | 1 (20.0%) |  |
| **Lymphocyte count X109** | NA (NA, NA) | NA (NA, NA) |  |
| **Addisons disease** |  |  | >0.9 |
| 0 | 0 (0.0%) | 0 (0.0%) |  |
| 1 | 3 (100.0%) | 5 (100.0%) |  |
| **ART exposure** | 0 (0.0%) | 1 (20.0%) | >0.9 |
| **Kidney medication** | 1 (33.3%) | 1 (20.0%) | >0.9 |
| **Rifampicin** | 0 (0.0%) | 0 (0.0%) | >0.9 |
| **Fluconazole** | 2 (66.7%) | 3 (60.0%) | >0.9 |
| **Opiates** | 1 (33.3%) | 2 (40.0%) | >0.9 |
| 1n (%); Median (IQR) | | | |
| 2Fisher's exact test | | | |

Mortality: Non-AI vs AI



|  | **Mortality: Non-AI vs AI** | | | **Mortality among only Addisons disease patients** | | |
| --- | --- | --- | --- | --- | --- | --- |
| Variable | **1**, N = 1281 | **2**, N = 81 | **p-value**2 | **Alive**, N = 171 | **Died**, N = 81 | **p-value**2 |
| **Age at enrolment, median (IQR) (years)** | 37 (32, 43) | 41 (37, 44) | 0.4 |  |  |  |
| **Gender, n(%)** |  |  | 0.7 |  |  | >0.9 |
| Female | 73 (57.0%) | 4 (50.0%) |  | 10 (58.8%) | 4 (50.0%) |  |
| Male | 55 (43.0%) | 4 (50.0%) |  | 7 (41.2%) | 4 (50.0%) |  |
| **Ethnicity, n(%)** |  |  | 0.6 |  |  | 0.2 |
| Black African | 107 (83.6%) | 6 (75.0%) |  | 16 (94.1%) | 6 (75.0%) |  |
| Other | 21 (16.4%) | 2 (25.0%) |  | 1 (5.9%) | 2 (25.0%) |  |
| **Duration of current illness, median (IQR) (days)** | 14 (14, 21) | 14 (11, 14) | 0.2 | 1,812.0 (346.0, 3,326.0) | 129.5 (8.5, 4,104.5) | 0.6 |
| **Random cortisol** | 513 (399, 637) | 307 (254, 339) | <0.001 | 294.0 (233.0, 381.0) | 306.5 (254.0, 338.8) | >0.9 |
| **Basal cortisol** | 482 (401, 599) | 284 (219, 332) | <0.001 | 300.0 (185.0, 350.0) | 283.5 (219.0, 331.5) | >0.9 |
| **Stimulated cortisol** | 749 (610, 904) | 375 (330, 429) | <0.001 | 379.0 (313.0, 463.0) | 375.0 (330.3, 428.8) | 0.7 |
| **ACTH** | 32 (21, 53) | 42 (24, 76) | 0.4 | 25.3 (14.1, 64.1) | 42.4 (24.2, 76.0) | 0.5 |
| **Weight loss** | 105 (89.7%) | 6 (75.0%) | 0.2 | 14 (82.4%) | 6 (75.0%) | >0.9 |
| **Viral load (log10 Copies/mL)** | 10.3 (7.6, 12.6) | NA (NA, NA) |  |  |  |  |
| 11.60516730587 |  |  |  | 1 (100.0%) | 0 (NA%) |  |
| **Tuberculosis** | 108 (84.4%) | 7 (87.5%) | >0.9 | 12 (70.6%) | 7 (87.5%) | 0.6 |
| **PTB** | 80 (62.5%) | 3 (37.5%) | 0.3 | 6 (35.3%) | 3 (37.5%) | >0.9 |
| **EPTB** | 26 (20.3%) | 4 (50.0%) | 0.071 | 6 (35.3%) | 4 (50.0%) | 0.7 |
| **Cryptococcus neoformans** | 6 (4.7%) | 4 (50.0%) | <0.001 | 6 (35.3%) | 4 (50.0%) | 0.7 |
| **Pneumonia** | 14 (10.9%) | 0 (0.0%) | >0.9 | 3 (17.6%) | 0 (0.0%) | 0.5 |
| **Staph aureus** | 0 (0.0%) | 0 (0.0%) |  | 1 (5.9%) | 0 (0.0%) | >0.9 |
| **Kaposis sarcoma** | 1 (0.8%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Cytomegalovirus** | 0 (0.0%) | 0 (0.0%) |  | 1 (5.9%) | 0 (0.0%) | >0.9 |
| **HSV** | 2 (1.6%) | 0 (0.0%) | >0.9 | 1 (5.9%) | 0 (0.0%) | >0.9 |
| **HepB** | 4 (3.1%) | 1 (12.5%) | 0.3 | 1 (5.9%) | 1 (12.5%) | >0.9 |
| **Candida** | 6 (4.7%) | 0 (0.0%) | >0.9 | 1 (5.9%) | 0 (0.0%) | >0.9 |
| **GE/c diff** | 1 (0.8%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Parvo B19** | 0 (0.0%) | 0 (0.0%) |  | 1 (5.9%) | 0 (0.0%) | >0.9 |
| **Syphilis** | 5 (3.9%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **B menigitis** | 1 (0.8%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **UTI / Leptospirosis** | 2 (1.6%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **PCP** | 2 (1.6%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **COVID-19** | 1 (0.8%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Neurocysticercosis** | 0 (0.0%) | 0 (0.0%) |  | 0 (0.0%) | 0 (0.0%) |  |
| **Total CD4 count** | 28 (10, 54) | 20 (17, 44) | >0.9 | 31.0 (11.0, 58.0) | 20.0 (16.5, 43.8) | >0.9 |
| **White cell count X109** | 5.2 (3.3, 7.8) | 8.3 (4.9, 34.5) | 0.12 | 4.0 (2.5, 6.2) | 8.3 (4.9, 34.5) | 0.057 |
| **Lymphocyte count X109** | 0.9 (0.4, 1.6) | NA (NA, NA) |  |  |  | >0.9 |
| 0.360000014305115 |  |  |  | 1 (20.0%) | 0 (NA%) |  |
| 0.490000009536743 |  |  |  | 1 (20.0%) | 0 (NA%) |  |
| 1.10000002384186 |  |  |  | 1 (20.0%) | 0 (NA%) |  |
| 1.30999994277954 |  |  |  | 1 (20.0%) | 0 (NA%) |  |
| 33.5999984741211 |  |  |  | 1 (20.0%) | 0 (NA%) |  |
| **Neutrophils** | 3 (2, 8) | NA (NA, NA) |  |  |  |  |
| **Sodium mmol/L** | 133.0 (129.0, 137.0) | 133.5 (132.5, 139.0) | 0.3 | 135.0 (134.0, 137.0) | 133.5 (132.5, 139.0) | 0.5 |
| **Potassium mmol/L** | 3.90 (3.50, 4.60) | 3.85 (3.52, 4.00) | 0.4 | 3.7 (3.2, 4.2) | 3.9 (3.5, 4.0) | 0.8 |
| **Haemoglobin g/dL** | 8.30 (7.15, 9.60) | 9.55 (7.60, 10.65) | 0.4 | 8.4 (7.6, 10.2) | 9.5 (7.6, 10.7) | 0.5 |
| **BP (systolic)** | 110 (100, 123) | 128 (115, 131) | 0.13 | 120.0 (111.0, 128.0) | 127.5 (115.0, 131.0) | 0.4 |
| **BP (diastolic)** | 70 (60, 80) | 74 (62, 79) | 0.8 | 73.0 (70.0, 80.0) | 73.5 (62.3, 79.3) | 0.7 |
| **Heart rate** | 94 (81, 111) | 87 (67, 101) | 0.3 | 87.0 (83.0, 114.0) | 87.0 (67.3, 101.3) | 0.4 |
| **Hypotension** | 14 (12.0%) | 0 (0.0%) | 0.6 | 0 (0.0%) | 0 (0.0%) |  |
| **Weakness** | 102 (87.2%) | 6 (75.0%) | 0.3 | 14 (82.4%) | 6 (75.0%) | >0.9 |
| **Tiredness** | 103 (88.8%) | 8 (100.0%) | >0.9 | 14 (82.4%) | 8 (100.0%) | 0.5 |
| **Poor appetite** | 97 (82.9%) | 8 (100.0%) | 0.4 | 13 (76.5%) | 8 (100.0%) | 0.3 |
| **Increased pigmentation of the skin** | 68 (59.6%) | 3 (42.9%) | 0.4 | 5 (33.3%) | 3 (42.9%) | >0.9 |
| **Nausea** | 70 (59.8%) | 6 (75.0%) | 0.5 | 9 (52.9%) | 6 (75.0%) | 0.4 |
| **Vomiting** | 34 (29.1%) | 2 (25.0%) | >0.9 | 6 (35.3%) | 2 (25.0%) | >0.9 |
| **Liking for salt** | 72 (62.1%) | 6 (75.0%) | 0.7 | 11 (64.7%) | 6 (75.0%) | >0.9 |
| **Hypoglycaemia** | 3 (2.6%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Loss of consciousness** | 4 (3.4%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Diarrhoea** | 58 (49.6%) | 2 (25.0%) | 0.3 | 5 (29.4%) | 2 (25.0%) | >0.9 |
| **Dizziness** | 61 (52.6%) | 4 (50.0%) | >0.9 | 8 (50.0%) | 4 (50.0%) | >0.9 |
| **Shock** | 2 (1.7%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Anorexia** | 61 (52.6%) | 3 (37.5%) | 0.5 | 4 (23.5%) | 3 (37.5%) | 0.6 |
| **Loss of axillary and pubic hair, if female** |  |  | 0.7 |  |  | >0.9 |
| No | 33 (27.7%) | 3 (37.5%) |  | 8 (47.1%) | 3 (37.5%) |  |
| Not applicable | 53 (44.5%) | 4 (50.0%) |  | 7 (41.2%) | 4 (50.0%) |  |
| Yes | 33 (27.7%) | 1 (12.5%) |  | 2 (11.8%) | 1 (12.5%) |  |
| **Any postural drop in blood pressure** | 7 (6.1%) | 0 (0.0%) | >0.9 | 1 (5.9%) | 0 (0.0%) | >0.9 |
| **Presence of anaemia** | 74 (63.8%) | 5 (62.5%) | >0.9 | 7 (43.8%) | 5 (62.5%) | 0.7 |
| **ART exposure** | 51 (39.8%) | 1 (12.5%) | 0.2 | 4 (23.5%) | 1 (12.5%) | >0.9 |
| **Kidney medication** | 14 (10.9%) | 2 (25.0%) | 0.2 | 3 (17.6%) | 2 (25.0%) | >0.9 |
| **incremental\_cortisol** | 249 (170, 358) | 41 (26, 142) | 0.002 | 122.0 (48.5, 179.0) | 41.0 (26.3, 141.8) | 0.4 |
| **Rifampicin** | 14 (10.9%) | 0 (0.0%) | >0.9 | 1 (5.9%) | 0 (0.0%) | >0.9 |
| **Fluconazole** | 18 (14.1%) | 5 (62.5%) | 0.004 | 5 (29.4%) | 5 (62.5%) | 0.2 |
| **Opiates** | 20 (15.6%) | 3 (37.5%) | 0.13 | 9 (52.9%) | 3 (37.5%) | 0.7 |
| **Age at enrolment median (IQR) (years)** |  |  |  | 35.0 (31.0, 47.0) | 40.5 (37.0, 43.5) | 0.6 |
| **Addisons disease** |  |  |  |  |  | 0.6 |
| PAI |  |  |  | 4 (23.5%) | 3 (37.5%) |  |
| SAI |  |  |  | 13 (76.5%) | 5 (62.5%) |  |
| 1Median (IQR); n (%) | | | | | | |
| 2Wilcoxon rank sum test; Fisher's exact test; Wilcoxon rank sum exact test | | | | | | |

# Table 4: Multivariate table mortality

iter imp variable 1 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 1 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 1 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 1 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 1 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 2 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 2 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 2 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 2 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 2 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 3 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 3 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 3 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 3 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 3 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 4 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 4 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 4 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 4 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 4 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 5 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 5 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 5 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 5 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 5 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 6 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 6 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 6 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 6 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 6 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 7 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 7 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 7 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 7 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 7 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 8 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 8 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 8 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 8 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 8 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 9 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 9 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 9 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 9 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 9 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 10 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 10 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 10 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 10 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 10 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 11 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 11 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 11 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 11 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 11 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 12 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 12 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 12 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 12 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 12 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 13 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 13 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 13 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 13 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 13 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 14 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 14 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 14 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 14 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 14 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 15 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 15 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 15 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 15 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 15 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 16 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 16 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 16 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 16 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 16 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 17 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 17 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 17 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 17 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 17 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 18 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 18 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 18 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 18 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 18 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 19 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 19 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 19 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 19 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 19 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 20 1 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 20 2 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 20 3 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 20 4 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count 20 5 Age\_at\_enrolment Basal\_cortisol ACTH BP\_diastolic Weakness Tiredness Poor\_appetite Increased\_pigmentation\_of\_the\_skin Nausea Liking\_for\_salt Loss\_of\_consciousness Diarrhoea Dizziness Shock Anorexia Loss\_of\_axillary\_and\_pubic\_hair Viral\_load CD4\_count Lymphocyte\_count

|  | **Bivariate** | | | | **multivariate - Cox PH** | | | **multivariate - Logistic** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Characteristic** | **N** | **HR**1 | **95% CI**1 | **p-value** | **HR**1 | **95% CI**1 | **p-value** | **OR**1 | **95% CI**1 | **p-value** |
| Age\_at\_enrolment | 399 | 1.01 | 0.99, 1.03 | 0.3 |  |  |  |  |  |  |
| Gender | 399 |  |  |  |  |  |  |  |  |  |
| Female |  | — | — |  |  |  |  |  |  |  |
| Male |  | 0.75 | 0.53, 1.05 | 0.090 |  |  |  |  |  |  |
| Ethnicity | 399 |  |  |  |  |  |  |  |  |  |
| Black African |  | — | — |  |  |  |  |  |  |  |
| Other |  | 1.00 | 0.64, 1.57 | >0.9 |  |  |  |  |  |  |
| Random\_cortisol | 377 | 1.07 | 1.02, 1.12 | 0.003 |  |  |  |  |  |  |
| Basal\_cortisol | 143 | 1.03 | 0.96, 1.11 | 0.4 | 1.04 | 0.98, 1.09 | 0.2 | 1.05 | 0.98, 1.12 | 0.15 |
| Stimulated\_cortisol | 139 | 1.00 | 0.93, 1.06 | >0.9 |  |  |  |  |  |  |
| ACTH | 377 | 1.25 | 1.03, 1.53 | 0.025 |  |  |  |  |  |  |
| BP\_systolic | 395 | 1.00 | 0.99, 1.01 | 0.4 |  |  |  |  |  |  |
| BP\_diastolic | 395 | 1.01 | 1.00, 1.02 | 0.060 |  |  |  |  |  |  |
| incremental\_cortisol | 133 | 0.90 | 0.80, 1.01 | 0.067 |  |  |  |  |  |  |
| Heart\_rate | 394 | 1.00 | 0.99, 1.01 | 0.6 |  |  |  |  |  |  |
| Hypotension | 377 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.68 | 0.96, 2.93 | 0.068 |  |  |  |  |  |  |
| Weakness | 378 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.00 | 0.60, 1.66 | >0.9 |  |  |  |  |  |  |
| Tiredness | 379 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.06 | 0.60, 1.89 | 0.8 |  |  |  |  |  |  |
| Poor\_appetite | 376 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.60 | 0.99, 2.58 | 0.055 |  |  |  |  |  |  |
| Weight\_loss | 380 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.65 | 0.37, 1.14 | 0.13 |  |  |  |  |  |  |
| Increased\_pigmentation\_of\_the\_skin | 365 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.50 | 1.04, 2.15 | 0.029 |  |  |  |  |  |  |
| Nausea | 379 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.42 | 0.99, 2.04 | 0.054 |  |  |  |  |  |  |
| Vomiting | 378 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.98 | 0.66, 1.44 | >0.9 |  |  |  |  |  |  |
| Liking\_for\_salt | 377 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.93 | 0.64, 1.34 | 0.7 |  |  |  |  |  |  |
| Hypoglycaemia | 377 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.00 | 0.32, 3.14 | >0.9 |  |  |  |  |  |  |
| Loss\_of\_consciousness | 376 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 3.34 | 1.23, 9.04 | 0.018 |  |  |  |  |  |  |
| Diarrhoea | 376 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.29 | 0.91, 1.83 | 0.2 |  |  |  |  |  |  |
| Dizziness | 377 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.29 | 0.90, 1.83 | 0.2 |  |  |  |  |  |  |
| Shock | 380 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 2.03 | 0.50, 8.20 | 0.3 |  |  |  |  |  |  |
| Anorexia | 377 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.32 | 0.93, 1.88 | 0.12 |  |  |  |  |  |  |
| Loss\_of\_axillary\_and\_pubic\_hair | 386 |  |  |  |  |  |  |  |  |  |
| No |  | — | — |  |  |  |  |  |  |  |
| Not applicable |  | 0.97 | 0.64, 1.48 | 0.9 |  |  |  |  |  |  |
| Yes |  | 1.74 | 1.09, 2.79 | 0.020 |  |  |  |  |  |  |
| Any\_postural\_drop\_in\_blood\_pressure | 376 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.62 | 0.75, 3.47 | 0.2 |  |  |  |  |  |  |
| Presence\_of\_anaemia | 375 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.49 | 1.03, 2.14 | 0.034 |  |  |  |  |  |  |
| Tuberculosis | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.76 | 0.48, 1.21 | 0.3 |  |  |  |  |  |  |
| PTB | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.86 | 0.61, 1.22 | 0.4 |  |  |  |  |  |  |
| EPTB | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.01 | 0.68, 1.52 | >0.9 |  |  |  |  |  |  |
| Cryptococcus neoformans | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.34 | 0.70, 2.54 | 0.4 |  |  |  |  |  |  |
| Pneumonia | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.68 | 0.39, 1.18 | 0.2 |  |  |  |  |  |  |
| Staph aureus | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.00 | 0.00, Inf | >0.9 |  |  |  |  |  |  |
| Kaposis sarcoma | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.91 | 0.13, 6.52 | >0.9 |  |  |  |  |  |  |
| Cytomegalovirus | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.00 | 0.00, Inf | >0.9 |  |  |  |  |  |  |
| HSV | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.91 | 0.23, 3.68 | 0.9 |  |  |  |  |  |  |
| HepB | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.12 | 0.46, 2.73 | 0.8 |  |  |  |  |  |  |
| Candida | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.02 | 0.45, 2.31 | >0.9 |  |  |  |  |  |  |
| GE/c diff | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.20 | 0.03, 1.43 | 0.11 |  |  |  |  |  |  |
| Parvo B19 | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.00 | 0.00, Inf | >0.9 |  |  |  |  |  |  |
| Syphilis | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.70 | 0.70, 4.16 | 0.2 |  |  |  |  |  |  |
| B menigitis | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.94 | 0.27, 13.9 | 0.5 |  |  |  |  |  |  |
| UTI / Leptospirosis | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.24 | 0.31, 5.03 | 0.8 |  |  |  |  |  |  |
| PCP | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 3.65 | 0.90, 14.8 | 0.069 |  |  |  |  |  |  |
| COVID-19 | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 3.82 | 0.53, 27.3 | 0.2 |  |  |  |  |  |  |
| Neurocysticercosis | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  |  |  |  |  |  |  |  |  |  |
| Viral\_load | 80 | 1.07 | 0.95, 1.20 | 0.3 | 1.01 | 0.94, 1.10 | 0.7 | 1.01 | 0.92, 1.11 | 0.9 |
| CD4\_count | 397 | 0.99 | 0.99, 1.00 | 0.070 | 1.00 | 0.99, 1.00 | 0.2 | 1.0 | 0.99, 1.00 | 0.2 |
| Sodium | 378 | 1.00 | 0.97, 1.03 | >0.9 |  |  |  |  |  |  |
| Potassium | 379 | 0.97 | 0.92, 1.03 | 0.4 |  |  |  |  |  |  |
| Haemoglobin | 396 | 0.94 | 0.87, 1.01 | 0.10 |  |  |  |  |  |  |
| White\_cell\_count | 392 | 1.00 | 1.00, 1.00 | 0.7 |  |  |  |  |  |  |
| Lymphocyte\_count | 83 | 0.99 | 0.94, 1.04 | 0.7 |  |  |  |  |  |  |
| ART exposure | 399 |  |  |  |  |  |  |  |  |  |
| No |  | — | — |  |  |  |  |  |  |  |
| Yes |  | 0.98 | 0.70, 1.39 | >0.9 |  |  |  |  |  |  |
| Kidney medication | 399 |  |  |  |  |  |  |  |  |  |
| No |  | — | — |  |  |  |  |  |  |  |
| Yes |  | 1.31 | 0.78, 2.21 | 0.3 |  |  |  |  |  |  |
| Rifampicin | 399 |  |  |  |  |  |  |  |  |  |
| No |  | — | — |  |  |  |  |  |  |  |
| Yes |  | 1.08 | 0.62, 1.88 | 0.8 |  |  |  |  |  |  |
| Fluconazole | 399 |  |  |  |  |  |  |  |  |  |
| No |  | — | — |  |  |  |  |  |  |  |
| Yes |  | 1.24 | 0.79, 1.94 | 0.4 |  |  |  |  |  |  |
| Opiates | 399 |  |  |  |  |  |  |  |  |  |
| No |  | — | — |  |  |  |  |  |  |  |
| Yes |  | 0.53 | 0.34, 0.84 | 0.006 |  |  |  |  |  |  |
| Addisons\_disease | 399 |  |  |  |  |  |  |  |  |  |
| 0 |  | — | — |  |  |  |  |  |  |  |
| 1 |  | 1.00 | 0.49, 2.04 | >0.9 |  |  |  |  |  |  |
| AI |  |  |  |  | 1.01 | 0.45, 2.27 | >0.9 |  |  |  |
| Cryptococcus\_neoformans |  |  |  |  | 1.41 | 0.70, 2.82 | 0.3 | 1.52 | 0.63, 3.58 | 0.3 |
| 1HR = Hazard Ratio, CI = Confidence Interval, OR = Odds Ratio | | | | | | | | | | |

|  | **Bivariate** | | | | **multivariate - Cox PH** | | | **multivariate - Logistic** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Characteristic** | **N** | **HR**1 | **95% CI**1 | **p-value** | **HR**1 | **95% CI**1 | **p-value** | **OR**1 | **95% CI**1 | **p-value** |
| Age\_at\_enrolment | 399 | 1.01 | 0.99, 1.03 | 0.3 |  |  |  |  |  |  |
| Gender | 399 |  |  |  |  |  |  |  |  |  |
| Female |  | — | — |  |  |  |  |  |  |  |
| Male |  | 0.75 | 0.53, 1.05 | 0.090 |  |  |  |  |  |  |
| Ethnicity | 399 |  |  |  |  |  |  |  |  |  |
| Black African |  | — | — |  |  |  |  |  |  |  |
| Other |  | 1.00 | 0.64, 1.57 | >0.9 |  |  |  |  |  |  |
| Random\_cortisol | 377 | 1.07 | 1.02, 1.12 | 0.003 |  |  |  |  |  |  |
| Basal\_cortisol | 143 | 1.03 | 0.96, 1.11 | 0.4 |  |  |  |  |  |  |
| Stimulated\_cortisol | 139 | 1.00 | 0.93, 1.06 | >0.9 |  |  |  |  |  |  |
| ACTH | 377 | 1.25 | 1.03, 1.53 | 0.025 |  |  |  |  |  |  |
| BP\_systolic | 395 | 1.00 | 0.99, 1.01 | 0.4 |  |  |  |  |  |  |
| BP\_diastolic | 395 | 1.01 | 1.00, 1.02 | 0.060 |  |  |  |  |  |  |
| incremental\_cortisol | 133 | 0.90 | 0.80, 1.01 | 0.067 | 1.00 | 1.00, 1.00 | 0.3 | 1.00 | 1.00, 1.00 | 0.4 |
| Heart\_rate | 394 | 1.00 | 0.99, 1.01 | 0.6 |  |  |  |  |  |  |
| Hypotension | 377 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.68 | 0.96, 2.93 | 0.068 |  |  |  |  |  |  |
| Weakness | 378 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.00 | 0.60, 1.66 | >0.9 |  |  |  |  |  |  |
| Tiredness | 379 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.06 | 0.60, 1.89 | 0.8 |  |  |  |  |  |  |
| Poor\_appetite | 376 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.60 | 0.99, 2.58 | 0.055 |  |  |  |  |  |  |
| Weight\_loss | 380 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.65 | 0.37, 1.14 | 0.13 |  |  |  |  |  |  |
| Increased\_pigmentation\_of\_the\_skin | 365 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.50 | 1.04, 2.15 | 0.029 |  |  |  |  |  |  |
| Nausea | 379 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.42 | 0.99, 2.04 | 0.054 |  |  |  |  |  |  |
| Vomiting | 378 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.98 | 0.66, 1.44 | >0.9 |  |  |  |  |  |  |
| Liking\_for\_salt | 377 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.93 | 0.64, 1.34 | 0.7 |  |  |  |  |  |  |
| Hypoglycaemia | 377 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.00 | 0.32, 3.14 | >0.9 |  |  |  |  |  |  |
| Loss\_of\_consciousness | 376 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 3.34 | 1.23, 9.04 | 0.018 |  |  |  |  |  |  |
| Diarrhoea | 376 |  |  |  | 0.88 | 0.46, 1.68 | 0.7 | 0.91 | 0.41, 2.03 | 0.8 |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.29 | 0.91, 1.83 | 0.2 |  |  |  |  |  |  |
| Dizziness | 377 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.29 | 0.90, 1.83 | 0.2 |  |  |  |  |  |  |
| Shock | 380 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 2.03 | 0.50, 8.20 | 0.3 |  |  |  |  |  |  |
| Anorexia | 377 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.32 | 0.93, 1.88 | 0.12 |  |  |  |  |  |  |
| Loss\_of\_axillary\_and\_pubic\_hair | 386 |  |  |  |  |  |  |  |  |  |
| No |  | — | — |  |  |  |  |  |  |  |
| Not applicable |  | 0.97 | 0.64, 1.48 | 0.9 |  |  |  |  |  |  |
| Yes |  | 1.74 | 1.09, 2.79 | 0.020 |  |  |  |  |  |  |
| Any\_postural\_drop\_in\_blood\_pressure | 376 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.62 | 0.75, 3.47 | 0.2 |  |  |  |  |  |  |
| Presence\_of\_anaemia | 375 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.49 | 1.03, 2.14 | 0.034 |  |  |  |  |  |  |
| Tuberculosis | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.76 | 0.48, 1.21 | 0.3 |  |  |  |  |  |  |
| PTB | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.86 | 0.61, 1.22 | 0.4 |  |  |  |  |  |  |
| EPTB | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.01 | 0.68, 1.52 | >0.9 |  |  |  |  |  |  |
| Cryptococcus neoformans | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.34 | 0.70, 2.54 | 0.4 |  |  |  |  |  |  |
| Pneumonia | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.68 | 0.39, 1.18 | 0.2 |  |  |  |  |  |  |
| Staph aureus | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.00 | 0.00, Inf | >0.9 |  |  |  |  |  |  |
| Kaposis sarcoma | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.91 | 0.13, 6.52 | >0.9 |  |  |  |  |  |  |
| Cytomegalovirus | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.00 | 0.00, Inf | >0.9 |  |  |  |  |  |  |
| HSV | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.91 | 0.23, 3.68 | 0.9 |  |  |  |  |  |  |
| HepB | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.12 | 0.46, 2.73 | 0.8 |  |  |  |  |  |  |
| Candida | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.02 | 0.45, 2.31 | >0.9 |  |  |  |  |  |  |
| GE/c diff | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.20 | 0.03, 1.43 | 0.11 |  |  |  |  |  |  |
| Parvo B19 | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 0.00 | 0.00, Inf | >0.9 |  |  |  |  |  |  |
| Syphilis | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.70 | 0.70, 4.16 | 0.2 |  |  |  |  |  |  |
| B menigitis | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.94 | 0.27, 13.9 | 0.5 |  |  |  |  |  |  |
| UTI / Leptospirosis | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 1.24 | 0.31, 5.03 | 0.8 |  |  |  |  |  |  |
| PCP | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 3.65 | 0.90, 14.8 | 0.069 |  |  |  |  |  |  |
| COVID-19 | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  | 3.82 | 0.53, 27.3 | 0.2 |  |  |  |  |  |  |
| Neurocysticercosis | 399 |  |  |  |  |  |  |  |  |  |
| FALSE |  | — | — |  |  |  |  |  |  |  |
| TRUE |  |  |  |  |  |  |  |  |  |  |
| Viral\_load | 80 | 1.07 | 0.95, 1.20 | 0.3 | 1.10 | 0.97, 1.25 | 0.14 | 1.14 | 0.97, 1.36 | 0.12 |
| CD4\_count | 397 | 0.99 | 0.99, 1.00 | 0.070 |  |  |  |  |  |  |
| Sodium | 378 | 1.00 | 0.97, 1.03 | >0.9 |  |  |  |  |  |  |
| Potassium | 379 | 0.97 | 0.92, 1.03 | 0.4 |  |  |  |  |  |  |
| Haemoglobin | 396 | 0.94 | 0.87, 1.01 | 0.10 |  |  |  |  |  |  |
| White\_cell\_count | 392 | 1.00 | 1.00, 1.00 | 0.7 |  |  |  |  |  |  |
| Lymphocyte\_count | 83 | 0.99 | 0.94, 1.04 | 0.7 |  |  |  |  |  |  |
| ART exposure | 399 |  |  |  |  |  |  |  |  |  |
| No |  | — | — |  |  |  |  |  |  |  |
| Yes |  | 0.98 | 0.70, 1.39 | >0.9 |  |  |  |  |  |  |
| Kidney medication | 399 |  |  |  |  |  |  |  |  |  |
| No |  | — | — |  |  |  |  |  |  |  |
| Yes |  | 1.31 | 0.78, 2.21 | 0.3 |  |  |  |  |  |  |
| Rifampicin | 399 |  |  |  |  |  |  |  |  |  |
| No |  | — | — |  |  |  |  |  |  |  |
| Yes |  | 1.08 | 0.62, 1.88 | 0.8 |  |  |  |  |  |  |
| Fluconazole | 399 |  |  |  |  |  |  |  |  |  |
| No |  | — | — |  |  |  |  |  |  |  |
| Yes |  | 1.24 | 0.79, 1.94 | 0.4 |  |  |  |  |  |  |
| Opiates | 399 |  |  |  |  |  |  |  |  |  |
| No |  | — | — |  |  |  |  |  |  |  |
| Yes |  | 0.53 | 0.34, 0.84 | 0.006 |  |  |  |  |  |  |
| Addisons\_disease | 399 |  |  |  |  |  |  |  |  |  |
| 0 |  | — | — |  |  |  |  |  |  |  |
| 1 |  | 1.00 | 0.49, 2.04 | >0.9 |  |  |  |  |  |  |
| AI |  |  |  |  | 0.70 | 0.22, 2.26 | 0.6 |  |  |  |
| Cryptococcus\_neoformans |  |  |  |  | 1.80 | 0.47, 6.85 | 0.4 | 2.06 | 0.49, 8.66 | 0.3 |
| Kidney\_medication |  |  |  |  | 1.82 | 0.73, 4.56 | 0.2 | 2.13 | 0.63, 7.10 | 0.2 |
| 1HR = Hazard Ratio, CI = Confidence Interval, OR = Odds Ratio | | | | | | | | | | |

[1] 0.8229594 [1] 0.8925738 [1] 0.4120505 png 2

# Table 5 univariate analysis for addisson’s disease

| **Characteristic** | **N** | **OR**1 | **95% CI**1 | **p-value** |
| --- | --- | --- | --- | --- |
| Age at enrolment | 547 | 1.02 | 0.98, 1.07 | 0.2 |
| Gender, n(%) | 548 |  |  |  |
| Female |  | — | — |  |
| Male |  | 0.97 | 0.44, 2.11 | >0.9 |
| Ethnicity, n(%) | 549 | 0.62 | 0.18, 1.64 | 0.4 |
| Duration of current illness, median (IQR) (days) | 514 | 1.00 | 0.98, 1.00 | 0.7 |
| Weight loss | 525 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.70 | 0.27, 2.13 | 0.5 |
| log10 viral load | 121 | 1.11 | 0.75, 1.84 | 0.6 |
| Tuberculosis | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.65 | 0.27, 1.82 | 0.4 |
| PTB | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.38 | 0.17, 0.82 | 0.015 |
| EPTB | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 2.51 | 1.08, 5.57 | 0.026 |
| Cryptococcus neoformans | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 14.8 | 5.88, 36.1 | <0.001 |
| Pneumonia | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.98 | 0.23, 2.92 | >0.9 |
| Staph aureus | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 42,526,536 | 0.00, NA | >0.9 |
| Kaposis sarcoma | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 3.98 | 0.20, 25.9 | 0.2 |
| Cytomegalovirus | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 42,526,536 | 0.00, NA | >0.9 |
| HSV | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 2.83 | 0.15, 16.8 | 0.3 |
| HepB | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 2.53 | 0.39, 9.57 | 0.2 |
| Candida | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.57 | 0.03, 2.82 | 0.6 |
| GE/c diff | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 |  | >0.9 |
| Parvo B19 | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 42,526,536 | 0.00, NA | >0.9 |
| Syphilis | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 |  | >0.9 |
| B menigitis | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 |  | >0.9 |
| UTI / Leptospirosis | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 |  | >0.9 |
| PCP | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 |  | >0.9 |
| COVID-19 | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 |  | >0.9 |
| Neurocysticercosis | 549 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 |  | >0.9 |
| Total CD4 count | 542 | 0.99 | 0.98, 1.01 | 0.4 |
| White cell count X109 | 538 | 1.00 | 1.00, 1.00 | 0.4 |
| Lymphocyte count X109 | 124 | 1.00 |  | 0.9 |
| Neutrophils | 126 | 0.24 | 0.02, 0.82 | 0.2 |
| Sodium mmol/L | 518 | 1.23 | 0.97, 1.54 | 0.089 |
| Potassium mmol/L | 516 | 0.96 | 0.55, 1.13 | 0.8 |
| Haemoglobin g/dL | 542 | 1.00 |  | 0.9 |
| BP (systolic) | 538 | 1.00 | 0.98, 1.02 | 0.7 |
| BP (diastolic) | 538 | 1.02 | 0.99, 1.05 | 0.2 |
| Any postural drop in blood pressure | 521 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.80 | 0.28, 6.63 | 0.4 |
| Heart rate | 537 | 1.00 | 0.98, 1.01 | 0.7 |
| Hypotension | 522 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.38 | 0.02, 1.83 | 0.3 |
| Weakness | 523 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.61 | 0.25, 1.72 | 0.3 |
| Tiredness | 524 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.01 | 0.37, 3.50 | >0.9 |
| Poor appetite | 520 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.40 | 0.56, 4.25 | 0.5 |
| Increased pigmentation of the skin | 510 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.58 | 0.24, 1.33 | 0.2 |
| Nausea | 523 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.29 | 0.59, 2.91 | 0.5 |
| Vomiting | 522 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.10 | 0.44, 2.49 | 0.8 |
| Liking for salt | 521 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 2.10 | 0.93, 5.18 | 0.085 |
| Hypoglycaemia | 521 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 |  | >0.9 |
| Loss of consciousness | 520 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 |  | >0.9 |
| Diarrhoea | 519 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.52 | 0.21, 1.18 | 0.13 |
| Dizziness | 520 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.09 | 0.49, 2.43 | 0.8 |
| Shock | 524 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 |  | >0.9 |
| Anorexia | 522 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.47 | 0.19, 1.06 | 0.079 |
| Presence of anaemia | 519 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.70 | 0.32, 1.56 | 0.4 |
| ART exposure | 549 |  |  |  |
| No |  | — | — |  |
| Yes |  | 0.46 | 0.17, 1.08 | 0.10 |
| Kidney medication | 549 |  |  |  |
| No |  | — | — |  |
| Yes |  | 2.30 | 0.74, 5.91 | 0.11 |
| mortality | 150 |  |  |  |
| no |  | — | — |  |
| yes |  | 1.30 | 0.39, 4.35 | 0.7 |
| 1OR = Odds Ratio, CI = Confidence Interval | | | | |

iter imp variable 1 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 1 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 1 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 1 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 1 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 2 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 2 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 2 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 2 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 2 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 3 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 3 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 3 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 3 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 3 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 4 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 4 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 4 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 4 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 4 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 5 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 5 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 5 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 5 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 5 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 6 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 6 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 6 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 6 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 6 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 7 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 7 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 7 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 7 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 7 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 8 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 8 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 8 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 8 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 8 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 9 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 9 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 9 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 9 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 9 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 10 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 10 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 10 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 10 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 10 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 11 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 11 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 11 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 11 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 11 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 12 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 12 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 12 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 12 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 12 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 13 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 13 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 13 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 13 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 13 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 14 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 14 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 14 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 14 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 14 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 15 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 15 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 15 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 15 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 15 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 16 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 16 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 16 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 16 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 16 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 17 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 17 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 17 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 17 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 17 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 18 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 18 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 18 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 18 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 18 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 19 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 19 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 19 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 19 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 19 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 20 1 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 20 2 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 20 3 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 20 4 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender 20 5 BP\_diastolic Weakness Diarrhoea Sodium Lymphocyte\_count Weight\_loss Anorexia Neutrophils Total.CD4.count Potassium Duration\_of\_current\_illness Age\_at\_enrolment Gender

| **Characteristic** | **OR**1 | **95% CI**1 | **p-value** |
| --- | --- | --- | --- |
| Potassium | 0.99 | 0.56, 1.17 | >0.9 |
| Neutrophils | 0.92 | 0.73, 1.05 | 0.4 |
| CD4\_count | 0.99 | 0.98, 1.01 | 0.4 |
| 1OR = Odds Ratio, CI = Confidence Interval | | | |